Valve performance matters from day one.

Sustained valve performance^◊ helps keep your patients alive and out of the hospital.¹

Durable valve performance, as defined by freedom from bioprosthetic valve dysfunction^◊ (BVD), is critical, regardless of the procedure or platform.¹

Evolut™ TAVR - a proven legacy of performance

Poor valve performance^◊ results in worse patient outcomes.¹

BVD imparts

50%

relative increase in hazard of any death or rehospitalization at 5 years.¹

A proven legacy of performance.

Valve performance starts the day of the procedure and continues for a lifetime.

Evolut™ TAVR delivers superior valve performance^‡ in patients with small annulus^¶ at one year versus SAPIEN™* platform.³

Explore the durability difference.

Five-year BVD between TAVR vs SAVR.

Poor valve performance^◊, regardless of therapy, results in worse clinical outcomes at 5 years.^§,+,1

Five-year BVD between TAVR vs SAVR

3x lower severe PPM versus SAVR at 30-day/discharge.

3.7% CoreValve™/Evolut™ TAVR
12.1% SAVR; p<0.001

Evolut™ TAVR is the only platform to demonstrate a performance and durability benefit over SAVR at 5 years in randomized clinical trials.^+,1

Evolut™ TAVR Low Risk Trial.

Strong clinical outcomes in low-risk patients at five years.⁵

5-year all-cause mortality or disabling stroke Evolut™ Low-Risk Trial.

Four-year low-risk patient outcomes

In low-risk patients at five years, vs. SAVR

Evolut™ TAVR delivers outstanding valve performance.^∥,5

16% lower mean gradients
10.7 mmHg Evolut™ TAVR vs 12.8 mmHg SAVR; p<0.001

11% larger EOAs
2.1 cm² Evolut™ TAVR vs. 1.9 cm² SAVR; p<0.001

Numerically lower rate of cardiovascular mortality⁵

7.2% Evolut™ TAVR vs.
9.3% SAVR; p = 0.15

TAVR risks may include, but are not limited to, death, stroke, damage to arteries, bleeding, and need for permanent pacemaker.

‡ Valve performance as defined as freedom from bioprosthetic valve dysfunction (BVD) through 12 months. BVD is defined as a composite including any of the following: hemodynamic structural valve dysfunction (mean gradient ≥ 20 mmHg), non-structural valve dysfunction (severe prothesis-patient mismatch or ≥ moderate aortic regurgitation), clinical thrombosis, endocarditis, and aortic valve reintervention.

§ Devices: Evolut R 73%/Evolut PRO 23.4%/CoreValve 3.6%

◊ Bioprosthetic Valve Dysfunction (BVD)² defined as: SVD (mean gradient ≥10 mmHg increase from 30-day/discharge to last echo AND ≥ 20 mmHg at last echo or new onset/ increase of ≥ moderate intraprosthetic aortic regurgitation), NSVD (severe PPM at 30-day/discharge or severe PVR through 5 years), clinical valve thrombosis, and endocarditis.

¶ In patients with small annuli (area ≤ 430 mm²) in all-comers trial, consisting of majority low surgical risk participants (52.1%).

+ In pooled analysis of intermediate- and high-risk patients.

|| Valve performance is defined as lower mean gradients and larger EOAs.

Yakubov SJ, Van Mieghem NM, Oh JK, et al. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. J Am Coll Cardiol. April 8, 2025;85(13):1419–1430.
Adapted from VARC-3 : Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol. 2021;77(21):2717–2746.
Herrmann HC, Mehran R, Blackman DJ, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. June 6 2024;390(21):1959–197.
Kornyeva A, Burri M, Lange R, Ruge H. Self-expanding vs. balloon expandable transcatheter heart valves in small aortic annuli. Front Cardiovasc Med. Aug 3, 2023;10:1175246.
Forrest, J, Yakubov, S, Deeb, G. et al. 5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. JACC. 2025 Apr, 85 (15) 1523–1532.

™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

UC202600895 EN 06/2025